Trending NewsTrending NewsNASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $277.79 -1.32 (-0.47%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Amgen Stock (NASDAQ:AMGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amgen alerts:Sign Up Key Stats Today's Range$276.64▼$281.3250-Day Range$262.28▼$297.2952-Week Range$253.30▼$346.85Volume867,714 shsAverage Volume2.82 million shsMarket Capitalization$149.37 billionP/E Ratio25.42Dividend Yield3.43%Price Target$307.82Consensus RatingHold Company OverviewAmgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More… Amgen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreAMGN MarketRank™: Amgen scored higher than 86% of companies evaluated by MarketBeat, and ranked 40th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 8 buy ratings, 12 hold ratings, and 2 sell ratings.Amount of Analyst CoverageAmgen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth3.73% Earnings GrowthEarnings for Amgen are expected to grow by 3.73% in the coming year, from $20.62 to $21.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 25.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 25.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.73.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.54. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 25.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.47% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Amgen has recently increased by 2.55%, indicating that investor sentiment is decreasing. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 3.40%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Amgen is 86.86%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 44.51% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Sustainability and ESG3.9 / 5Environmental Score-2.42 Percentage of Shares Shorted2.47% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Amgen has recently increased by 2.55%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment1.07 News SentimentAmgen has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.95 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 82 news articles for Amgen this week, compared to 40 articles on an average week.Search InterestOnly 41 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -2% compared to the previous 30 days.MarketBeat FollowsOnly 25 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $434,520.00 in company stock.Percentage Held by InsidersOnly 0.76% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Email Address AMGN Stock News HeadlinesAmgen (AMGN) Receives a Buy from Evercore ISIJune 27 at 3:54 AM | theglobeandmail.comGuggenheim Remains a Hold on Amgen (AMGN)June 27 at 3:54 AM | theglobeandmail.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 27 at 2:00 AM | Investors Alley (Ad)5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallJune 26 at 12:48 PM | msn.comWilliam Blair Reaffirms Outperform Rating for Amgen (NASDAQ:AMGN)June 26 at 3:17 AM | americanbankingnews.comIn the wake of Amgen Inc.'s (NASDAQ:AMGN) latest US$6.5b market cap drop, institutional owners may be forced to take severe actionsJune 25 at 11:11 PM | finance.yahoo.comAmgen (AMGN) Stock Moves 1.03%: What You Should KnowJune 25 at 11:11 PM | msn.comAmgen (AMGN) Falls 5.8% as Novo Nordisk Hammers Its Weight Loss Drug TrialJune 24 at 5:26 PM | msn.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $260.64 at the start of the year. Since then, AMGN shares have increased by 7.6% and is now trading at $280.4150. View the best growth stocks for 2025 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Thursday, May, 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. The company's revenue was up 9.4% compared to the same quarter last year. Read the conference call transcript. Does Amgen have any subsidiaries? The following companies are subsidiaries of Amgen: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Top institutional investors of Amgen include Vanguard Group Inc. (9.83%), Primecap Management Co. CA (2.30%), Charles Schwab Investment Management Inc. (2.27%) and Northern Trust Corp (1.15%). Insiders that own company stock include Amgen Inc, Murdo Gordon, David M Reese, Jonathan P Graham, Robert Eckert, Rachna Khosla, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/01/2025Record date for 6/6 Dividend5/16/2025Ex-Dividend for 6/6 Dividend5/16/2025Dividend Payable6/06/2025Today6/27/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees28,000Year Founded1980Price Target and Rating Average Stock Price Target$307.82 High Stock Price Target$383.00 Low Stock Price Target$195.00 Potential Upside/Downside+9.9%Consensus RatingHold Rating Score (0-4)2.35 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$10.96 Trailing P/E Ratio25.56 Forward P/E Ratio13.59 P/E Growth2.54Net Income$4.09 billion Net Margins17.39% Pretax Margin19.49% Return on Equity176.11% Return on Assets12.39% Debt Debt-to-Equity Ratio8.70 Current Ratio1.17 Quick Ratio0.88 Sales & Book Value Annual Sales$34.13 billion Price / Sales4.41 Cash Flow$30.36 per share Price / Cash Flow9.23 Book Value$10.93 per share Price / Book25.63Miscellaneous Outstanding Shares537,706,000Free Float533,619,000Market Cap$150.65 billion OptionableOptionable Beta0.51 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:AMGN) was last updated on 6/27/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.